Corre Camille S, Matern Dietrich, Pellegrino Joan E, Saavedra-Matiz Carlos A, Orsini Joseph J, Thompson-Stone Robert
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Int J Neonatal Screen. 2021 May 28;7(2):28. doi: 10.3390/ijns7020028.
Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient's evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring.
克拉伯病(KD)是一种罕见的遗传性神经退行性疾病,由半乳糖脑苷脂酶活性缺乏引起,可在婴儿早期出现,需要紧急转诊进行造血干细胞移植,也可在生命后期出现。KD的新生儿筛查(NBS)需要根据实验室值对患者进行识别和风险分层,以预测疾病在婴儿早期或生命后期的发病情况。生物标志物半乳糖鞘氨醇在NBS算法中起着关键作用,以确定早发性疾病的可能性。本报告描述了一名在纽约州KD筛查呈阳性的患者,其基因型可能致病,酶活性明显降低,但半乳糖鞘氨醇水平出奇地低。该患者最终在婴儿晚期患上了KD,这一结果并未被现有的NBS算法明确预测。至关重要的是,理想情况下,应与KD专家协商,结合基因型、酶活性水平和患者不断变化的临床表现来评估半乳糖鞘氨醇水平,以指导诊断和监测计划。